No Data
Keybanc Maintains Overweight on Simulations Plus, Raises Price Target to $37
KeyBanc Maintains Simulations Plus(SLP.US) With Buy Rating, Raises Target Price to $37
Simulations Plus Teams With ETC to Advance IVIVC in Drug Delivery
Simulations Plus And Enabling Technologies Consortium Announce Strategic Collaboration To Advance GastroPlus Enhancements
Express News | Simulations Plus and Enabling Technologies Consortium Announce Strategic Collaboration to Advance Gastroplus® Enhancements
The Returns On Capital At Simulations Plus (NASDAQ:SLP) Don't Inspire Confidence